Hua Medicine
- Biotech or pharma, therapeutic R&D
Hua Medicine is a leading innovative drug development company in China focused on novel therapies for the treatment of diabetes, metabolism and other chronic disorders. Founded by an experienced group of entrepreneurs and international investment firms, Hua has advanced a first-in-class (glucokinase activator) oral drug dorzagliatin for the treatment of Type 2 Diabetes (T2D), which has been approved in China and is included on the China National Reimbursement List. Dorzagliatin (aka HuaTangNing in mainland China) is the only approved T2D drug with published data from its registrational Ph3 trials to demonstrate a 52-week drug-free remission diabetes treatment from its participating T2D diabetes in one of its Ph3 trials. HuaTangNing is available in over 2,500 hospitals in China and has been prescribed to over 200,000 patients in China already.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}